• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Cellebrite (CLBT) Using Drone Forensics To Deepen Its AI Cloud Investigation Moat?

    Simply Wall St·08/08/2026 11:28:15
    语音播报
    • Cellebrite DI recently expanded its exclusive partnership with SkySafe to strengthen drone detection and airspace intelligence tools used in digital investigations, and the company is set to release its second-quarter 2026 results on August 13, 2026.
    • This combination of product expansion into drone-related forensics and an imminent earnings update highlights how Cellebrite is positioning its platform for emerging investigative needs.
    • We'll now examine how the expanded SkySafe partnership could influence Cellebrite's investment narrative around AI-enabled, cloud-based investigative tools.

    AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Cellebrite DI Investment Narrative Recap

    To own Cellebrite DI, you need to believe its AI driven, cloud based tools will remain essential to digital investigations despite regulatory, security, and government budget headwinds. The expanded SkySafe partnership supports that thesis at the product level, but it does not materially change the near term catalyst of the August 13, 2026 earnings release or the key risk tied to uneven U.S. federal spending and contract timing.

    The SkySafe expansion fits alongside Cellebrite’s broader product push, including Genesis and Guardian, to extend its platform across more evidence types and workflows. For investors watching catalysts, this matters because it shows how Cellebrite is trying to deepen its role in complex investigations while FedRAMP High authorization and U.S. federal cloud adoption remain central to the medium term earnings story.

    Yet despite this product progress, investors should be aware that...

    Read the full narrative on Cellebrite DI (it's free!)

    Cellebrite DI's narrative projects $803.2 million revenue and $136.3 million earnings by 2029. This requires 17.4% yearly revenue growth and about a $64.9 million earnings increase from $71.4 million today.

    Uncover how Cellebrite DI's forecasts yield a $21.00 fair value, a 31% upside to its current price.

    Exploring Other Perspectives

    CLBT 1-Year Stock Price Chart
    CLBT 1-Year Stock Price Chart

    Some of the lowest ranked analysts take a much more cautious view, assuming revenue of about US$803.3 million and earnings of roughly US$123.4 million by 2029, and they worry that rising encryption and privacy rules could blunt the benefits of deals like SkySafe, so it is worth weighing these more pessimistic expectations against the more optimistic consensus before deciding how this new partnership might alter the story.

    Explore 4 other fair value estimates on Cellebrite DI - why the stock might be worth as much as 38% more than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    No Opportunity In Cellebrite DI?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.